Key statistics dashboard for Lipocine Inc. (LPCN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement.
Stock Data
| Price | $2.16 |
| Market Cap | $18M |
| Beta | 1.09 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.16 |
| Price / Book | 0.82 |
| P/S | 11.35 |
| P/FCF | -1.59 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 98.10% |
| EBIT Margin | -755.11% |
| EBITDA Margin | -751.38% |
| Operating Margin | -800.82% |
| Net Margin | -755.13% |
Financial Health
| Current Ratio | 11.48 |
| Quick Ratio | 11.48 |
| Cash Ratio | 2.41 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.19 |
| Book Value per share | 2.65 |
| Cash per share | 2.83 |
| FCF per share | -1.36 |
| Tangible Book Value per share | 2.65 |
| Dividend per share | 0.00 |
Related companies: ADAP · ANL · BLRX · EDSA · ERNA · GOVX · LNAI
Explore sector: Healthcare · Biotechnology
More sections of LPCN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks